| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.12 | 0.007 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.007 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.085 | 0.007 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.007 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.007 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.076 | 0.008 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.008 |